Neumora Therapeutics Shares Rise on Positive Obesity Drug Results
Dow Jones2026/07/27 14:23By Katherine Hamilton
Neumora Therapeutics shares rose after the company shared favorable results from a product being designed to treat obesity.
The stock advanced 6% to $1.58 on Monday. Shares are down 5% this year.
The oral inhibitor NMRA-215 was tested in a 13-week toxicology study of 162 rats. No instances of unexpected adverse findings were observed during the trial.
This comes after a study of 142 rats resulted in unexpected adverse findings in five animals.
Given the latest results, in combination with results from dog trials, Neumora believes the adverse findings in the earlier study weren't related to NMRA-215.
The company plans to submit an investigational new drug application for NMRA-215 in the fourth quarter of this year.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
July 27, 2026 10:23 ET (14:23 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AMD and Micron Get New Price Targets as Taiwan Chip Exports Hit Record $30.8B
--BankUnited Keeps Quarterly Dividend at $0.33 a Share, Payable Oct. 30 to Holders of Record Oct. 9
NASDAQ TRADE HALT <JSPRW.O> TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 04:00 PM
Crypto prices
More
